These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31092417)

  • 1. Clinical Outcomes of Recombinant Human-soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors.
    Kashiwagi S; Asano Y; Takahashi K; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
    Anticancer Res; 2019 May; 39(5):2259-2264. PubMed ID: 31092417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.
    Ouchi K; Takahashi S; Chikamatsu S; Ito S; Takahashi Y; Kawai S; Okita A; Kasahara Y; Okada Y; Imai H; Komine K; Saijo K; Takahashi M; Shirota H; Takahashi M; Gamoh M; Ishioka C
    Int J Clin Oncol; 2018 Aug; 23(4):790-798. PubMed ID: 29511940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
    Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
    Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.
    Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H
    Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
    Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
    Hashimoto D; Chikamoto A; Miyanari N; Ohara C; Kuramoto M; Horino K; Ohshima H; Baba H
    J Surg Res; 2015 Aug; 197(2):405-11. PubMed ID: 25972310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Human Soluble Thrombomodulin Contributes to a Reduction In-Hospital Mortality of Acute Cholangitis with Disseminated Intravascular Coagulation: A Propensity Score Analyses of a Japanese Nationwide Database.
    Tarasawa K; Fujimori K; Fushimi K
    Tohoku J Exp Med; 2020 Sep; 252(1):53-61. PubMed ID: 32879147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
    Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y
    Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognosis of disseminated intravascular coagulation associated with hematologic malignancy and its response to recombinant human thrombomodulin.
    Kurita N; Sakamoto T; Kato T; Kusakabe M; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Thromb Res; 2019 Jan; 173():57-64. PubMed ID: 30472436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
    Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
    J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of recombinant human soluble thrombomodulin in patients with solid carcinoma with DIC].
    Asano Y; Kashiwagi S; Shibutani M; Yamazoe S; Noda S; Sakurai K; Nagahara H; Kimura K; Kawajiri H; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohtani H; Takashima T; Yashiro M; Onoda N; Maeda K; Ohira M; Hirakawa K
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2503-5. PubMed ID: 25731571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Recombinant Human Soluble Thrombomodulin in Treating Disseminated Intravascular Coagulation Complicating Allogeneic Hematopoietic Stem Cell Transplantation.
    Inoue Y; Matsunawa M; Sano F; Miura I
    Acta Haematol; 2018; 140(2):121-127. PubMed ID: 30227394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of recombinant thrombomodulin administration on disseminated intravascular coagulation due to severe acute cholangitis (Recover-AC study).
    Ogura T; Eguchi T; Nakahara K; Kanno Y; Omoto S; Itonaga M; Kuroda T; Hakoda A; Ikeoka S; Takagi M; Okada A; Sato J; Morita R; Michikawa Y; Ito K; Koshita S; Takenaka M; Kitano M; Koizumi M; Higuchi K
    J Hepatobiliary Pancreat Sci; 2023 Feb; 30(2):221-228. PubMed ID: 34021720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.
    Tagami T; Matsui H; Horiguchi H; Fushimi K; Yasunaga H
    J Thromb Haemost; 2015 Jan; 13(1):31-40. PubMed ID: 25393713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.
    Tamura K; Saito H; Asakura H; Okamoto K; Tagawa J; Hayakawa T; Aoki N
    Int J Clin Oncol; 2015 Aug; 20(4):821-8. PubMed ID: 25385713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients.
    Miyoshi S; Ito R; Katayama H; Dote K; Aibiki M; Hamada H; Okura T; Higaki J
    Drug Des Devel Ther; 2014; 8():1211-9. PubMed ID: 25214765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yoshimura J; Yamakawa K; Ogura H; Umemura Y; Takahashi H; Morikawa M; Inoue Y; Fujimi S; Tanaka H; Hamasaki T; Shimazu T
    Crit Care; 2015 Mar; 19(1):78. PubMed ID: 25883031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.
    Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T
    Crit Care; 2011; 15(3):R123. PubMed ID: 21569368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
    Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
    BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.